Datasheet

Aven Antibody
CATALOG NUMBER: 2413

Availability: In stock

$0.00
Product Price Options
$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
TESTED APPLICATIONS:ELISA, IF, IHC-P, WB
APPLICATIONS:Aven antibody can be used for detection of Aven by Western blot at 1 μg/mL. Despite its predicted molecular weight, Aven often migrates at 55 kDa in SDS-PAGE. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1207 - Raji Cell Lysate
 2) Cat. No. 1306 - Human Spleen Tissue Lysate
 3) Cat. No. 10-901 - Human Spleen Tissue Slide
IMMUNOGEN:Aven antibody was raised against a 14 amino acid synthetic peptide from near the carboxy terminus of human Aven.

The immunogen is located within the last 50 amino acids of Aven.
HOST SPECIES:Rabbit

Properties

PURIFICATION:Aven Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:Aven Antibody is supplied in PBS containing 0.02% sodium azide.
STORAGE CONDITIONS:Aven antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:Aven Antibody: PDCD12, Cell death regulator Aven
ACCESSION NO.:NP_065104
PROTEIN GI NO.:9966841
OFFICIAL SYMBOL:AVEN
GENE ID:57099

Background

BACKGROUND:Aven Antibody: Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells. Disruption of this process has been implicated in a variety of diseases such as cancer. Aven is a recently discovered protein that blocks apoptosis induced by Apaf-1 and caspase-9. It is thought that Aven functions by binding to Bcl-xL, an antiapoptotic member of the Bcl-2 family, and to Apaf-1, possibly interfering with the ability of Apaf-1 to self-associate, suggesting that Aven impedes Apaf-1-mediated caspase activation. Higher levels of Aven mRNA are seen in patients with acute leukemia than in control patients, suggesting that Aven may be useful as a prognostic indicator in leukemia patients.
REFERENCES: 1) Lockshin RA, Osborne B, and Zakeri Z. Cell death in the third millennium. Cell Death Differ. 2000; 7:2-7.
2) Chau BN, Cheng EH-Y, Kerr DA, et al. Aven, a novel inhibitor of caspase activation. Binds Bcl-xL and Apaf-1. Mol. Cell 2000; 6:31-40.
3) Paydas S, Tanriverdi K, Yavuz S, et al. Survivin and aven: two distinct antiapoptotic signals in acute leukemias. Ann. Oncology 2003; 14:1045-50.

For Research Use Only